1) Leukotriene modifier
白三稀受体拮抗剂
2) Leukotriene receptor antagonists
白三烯受体拮抗剂
1.
Application of leukotriene receptor antagonists in childhood disease
白三烯受体拮抗剂在儿科疾病中的应用现状
2.
RESULTS & CONCLUSION:Leukotriene receptor antagonists have become the most effective mediator antagonists in clinic treatment of asthma and which are currently widely used in the clinic.
目的:评价白三烯受体拮抗剂的临床应用概况。
3.
OBJECTIVE: To evaluate the efficacy and safety of leukotriene receptor antagonists (LTRAs) for exercise-induced asthma (EIA).
已有两篇Cochrane系统评价证实白三烯受体拮抗剂单独或联合吸入糖皮质激素治疗可使哮喘患者中度获益。
3) Leukotriene receptor antagonist
白三烯受体拮抗剂
1.
Protective effect of ONO-1078,a leukotriene receptor antagonist,on focal cerebral ischemia induced by endothelin-1 in rats;
白三烯受体拮抗剂ONO-1078对内皮素-1诱导的大鼠局灶性脑缺血的保护作用
2.
Effect of leukotriene receptor antagonist on cough variant asthma
白三烯受体拮抗剂对咳嗽变异性哮喘的作用
3.
Objective: To investigate the influence of the leukotriene receptor antagonist (montelukast) on airway remodeling and the expression of cyclin D1 in a murine model of asthma, and to explore the role of montelukast in dealing with asthma.
目的:研究应用白三烯受体拮抗剂(孟鲁司特钠)对哮喘小鼠肺组织中细胞周期蛋白D1(CyclinD1)的表达影响及对支气管哮喘气道重塑的作用,探讨白三烯受体拮抗剂在哮喘治疗中的作用。
4) leukotrienes receptor antagonist
白三烯受体拮抗剂
1.
Effect of leukotrienes receptor antagonist on the expressional levels of matrix metalloproteinase- 9 and its inhibitor TIMP- 1 in rats with asthma;
白三烯受体拮抗剂对哮喘大鼠基质金属蛋白酶-9及其抑制剂表达的影响
2.
METHODS:The literatures about leukotrienes receptor antagonists at home and abroad were reviewed,analyzed and summarized.
目的 :评价白三烯受体拮抗剂在治疗哮喘中的进展和临床应用。
5) leukotrienes D 4 receptor antagonist
白三烯D4受体拮抗剂
6) cysteinyl leukotriene receptor antagonist
半胱氨酰白三烯受体拮抗剂
1.
Aim To determine whether pranlukast (ONO-1078), a cysteinyl leukotriene receptor antagonist, possesses therapeutic effect when administered after focal cerebral ischemia in mice.
目的 观察半胱氨酰白三烯受体拮抗剂pranlukast(ONO 10 78)在小鼠局灶性脑缺血后的治疗作用。
补充资料：痰稀白
痰稀白 痰稀白 病状名。指属湿痰、寒痰。若兼咳而声音重浊，鼻塞，多为外感风寒。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条